TRIPLE NEGATIVE BREAST CANCER

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers such as breast, kidney, ovarian, head and neck, colorectal, lung, and skin cancer. The main goal was to check safety and find the right dose. The …

This early-phase study tested a new drug called FAZ053, alone or with another drug (PDR001), in 154 adults with advanced solid tumors (including triple-negative breast cancer and rare sarcomas). The main goal was to check safety and find the right dose. The drug works by helping …

This study tested a new drug called OC-001, given alone or with an immunotherapy drug (Avelumab), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The study was stopped early and involved 73 participants with v…

This early-phase study tested a new daily pill, NKT3447, in 23 adults with advanced solid tumors (like ovarian, endometrial, or lung cancer) that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was stopped early, so r…

This study tested a mix of chemotherapy (docetaxel), an immunotherapy drug (pembrolizumab), and a gene therapy (IL-12) in 8 women with a tough-to-treat type of breast cancer that had stopped responding to standard treatment. The goal was to see if this combination could shrink or…

This study looked at whether giving a two-week 'window' of the immunotherapy drug atezolizumab alone before starting chemotherapy could improve outcomes for people with triple-negative breast cancer. The trial enrolled 442 participants and compared this approach to starting atezo…

This study tested a combination of two drugs, ZEN003694 and talazoparib, in people with triple-negative breast cancer who do not have BRCA gene mutations. The goal was to see if the combination could shrink tumors or slow the disease. The trial was terminated early, so results ar…

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This study tested a drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to other treatments. The goal was to see if the drug could shrink tumors. However, the trial was stopped earl…

This study tested a drug called magrolimab combined with chemotherapy for people with advanced triple-negative breast cancer that cannot be removed by surgery. The goal was to see if the combination was safe and worked better than chemotherapy alone. The trial was stopped early, …

This study tested whether injecting a drug called vidutolimod directly into tumors, combined with an intravenous immunotherapy (cemiplimab), could shrink or control advanced cancers like Merkel cell carcinoma, skin cancer, breast cancer, and lung cancer. The trial enrolled 77 adu…

This early-phase study tested a new drug, BT-001, injected directly into tumors of people with advanced solid cancers (like melanoma or lung cancer). Some participants also received the immunotherapy pembrolizumab. The goal was to check safety and find the right dose. The study w…

This study tested a new drug called NUV-868, alone or combined with other cancer drugs (olaparib or enzalutamide), in people with advanced solid tumors like ovarian, pancreatic, prostate, or breast cancer. The main goals were to check safety and find the right dose. The study was…

This early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, so resul…